Clin Mol Hepatol.
2021 Jan;27(1):87-90. 10.3350/cmh.2020.0302.
Metabolic disease as a risk of hepatocellular carcinoma
- Affiliations
-
- 1Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka-sayama, Japan
- KMID: 2511454
- DOI: http://doi.org/10.3350/cmh.2020.0302
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Metabolic dysfunction-associated fatty liver disease is a ubiquitous latent cofactor in viral- and alcoholic-related hepatocellular carcinoma: Editorial on “Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis”
- Metformin and statins and their role in reducing hepatocellular carcinoma risk: Randomized trials are needed: Editorial on “Metformin and statins reduce hepatocellular carcinoma risk in chronic hepatitis C patients with failed antiviral therapy”
- Non-alcoholic Fatty Liver Disease and Hepatocellular Carcinoma
- Risk of Hepatocellular Carcinoma in Patients with Non-alcoholic Fatty Liver Disease
- The Development of Hepatocellular Carcinoma in Non-alcoholic Fatty Liver Disease
